comparemela.com

Latest Breaking News On - Alnylam pharmaceuticals company profile - Page 1 : comparemela.com

Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Sells 21,700 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares of the company’s […]

Amyw-schulman
Securities-exchange-commission
Allspring-global-investments-holdings
Nasdaq
Altitude-crest-partners-inc
Alnylam-pharmaceuticals-stock-down
Alnylam-pharmaceuticals-inc
Quent-capital
Citigroup
Investment-management
Wells-fargo-company

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Amy W. Schulman Sells 21,700 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now owns 8,436 shares of […]

Wellington
New-zealand-general
New-zealand
Amyw-schulman
William-blair
Pricet-rowe-associates-inc
Wellington-management-group
Alnylam-pharmaceuticals-trading-down
News-ratings-for-alnylam-pharmaceuticals-daily
Alnylam-pharmaceuticals-inc
Capital-international-investors
Nasdaq

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Westpac Banking Corp

Westpac Banking Corp increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 59.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,512 shares of the biopharmaceutical company’s stock after acquiring an additional 566 shares during the […]

Canada
William-blair
Forum-financial-management
Alnylam-pharmaceuticals-trading-down
News-ratings-for-alnylam-pharmaceuticals-daily
Nasdaq
Capital-management-inc
Securities-exchange-commission
Alnylam-pharmaceuticals-company-profile
Royal-bank
Westpac-banking-corp
Morgan-stanley

Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases Quarterly Earnings Results, Beats Expectations By $0.23 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23, Briefing.com reports. The firm had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. During the same […]

William-blair
Cantor-fitzgerald
News-ratings-for-alnylam-pharmaceuticals-daily
Alnylam-pharmaceuticals-company-profile
Earnings-history-for-alnylam-pharmaceuticals
Jpmorgan-chase-co
Alnylam-pharmaceuticals-inc
Alnylam-pharmaceuticals
Alnylam-pharmaceuticals-stock
Goldman-sachs-group
Get-free-report
Alnylam-pharmaceuticals-daily

Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at Chardan Capital

Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at Chardan Capital
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Canada
William-blair
Alnylam-pharmaceuticals
Alnylam-pharmaceuticals-inc
Ep-wealth-advisors
Royal-bank
Oppenheimer-co
Harbor-capital-advisors-inc
Alnylam-pharmaceuticals-company-profile
Analyst-recommendations-for-alnylam-pharmaceuticals
Institutional-investors-weigh-in-on-alnylam-pharmaceuticals
Wells-fargo-company
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.